Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News OptiNose Inc OPTN

Healthcare
OptiNose, Inc. is a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and... see more

Recent & Breaking News (NDAQ:OPTN)

Optinose Announces Pricing of Public Offering of Common Stock

GlobeNewswire November 21, 2019

Optinose Announces Proposed Public Offering of Common Stock

GlobeNewswire November 20, 2019

Optinose Reports Third Quarter 2019 Financial Results and Recent Operational Highlights

GlobeNewswire November 12, 2019

Optinose to Report Third Quarter 2019 Financial Results and Corporate Updates on November 12, 2019

GlobeNewswire November 1, 2019

Optinose Appoints Michael Richardson to New Position of Vice President, Business Development

GlobeNewswire October 4, 2019

Optinose to Present at the 2019 Cantor Global Healthcare Conference

GlobeNewswire September 27, 2019

Currax(TM) Pharmaceuticals LLC Announces First Acquisition: Acquires North American Rights to ONZETRA® Xsail®

PR Newswire September 26, 2019

OptiNose Announces License Agreement Related to ONZETRA XSAIL

GlobeNewswire September 26, 2019

Optinose Announces Departure of Chief Commercial Officer

GlobeNewswire September 17, 2019

Optinose Announces $150 Million Debt Financing from Pharmakon

GlobeNewswire September 12, 2019

Optinose Reports Second Quarter 2019 Financial Results and Recent Operational Highlights

GlobeNewswire August 12, 2019

Optinose to Report Second Quarter 2019 Financial Results and Corporate Updates on August 12, 2019

GlobeNewswire August 1, 2019

Optinose to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference

GlobeNewswire June 20, 2019

Optinose Named a 2019 Best Place to Work by Philadelphia Business Journal

GlobeNewswire June 19, 2019

Optinose Reports First Quarter 2019 Financial Results and Recent Operational Highlights

GlobeNewswire May 9, 2019

Optinose to Report First Quarter 2019 Financial Results and Corporate Updates on May 9, 2019

GlobeNewswire April 25, 2019

 Optinose Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Operational Highlights

GlobeNewswire March 6, 2019

Optinose to Report Fourth Quarter 2018 Financial Results and Corporate Updates on March 6, 2019

GlobeNewswire February 27, 2019

Optinose to Highlight Data at the 2019 AAAAI Annual Meeting in San Francisco

GlobeNewswire February 15, 2019

Optinose Announces License Agreement

GlobeNewswire February 4, 2019